Company

Companies of New York

Agenus

Agenus

Healthcare

Connections 1

Subscribe To favorites

Description

Agenus Inc. is a Lexington, Massachusetts-based biotechnology company focused on immunotherapy including immuno-oncology, a field that uses the immune system to control or cure cancer. The company is developing checkpoint modulators (CPMs), patient-specific anti-cancer vaccines, and adjuvants that can be used with a range of vaccines. CPM development is a particularly fast-moving field, since early products have produced unprecedented clinical benefits for patients.

History

Agenus was founded in 1994 by Garo H. Armen and Pramod K. Srivastava. The company has pioneered immunotherapies, including heat shock protein-based cancer vaccines, a program that has developed into its Prophage Series of personalized anti-cancer vaccines. Antigenics became a public company in February 2000 on the NASDAQ exchange with the ticker symbol AGEN. In 2000 Agenus acquired Aquila Biopharmaceuticals and a year later it acquired Aronex Pharmaceuticals. In February 2014 the company acquired a European firm, 4-Antibody, along with their portfolio of checkpoint modulators (CPMs) and a platform (Retrocyte Display® technology) to rapidly and efficiently discover new antibodies.

In October 2013, Agenus CEO Garo Armen issued a press release revealing that after an 18-month follow up on the RTS,S Malaria vaccine using QS21-Stimulon®, it was working well enough to support a regulatory filing in 2014. This was the first proof of the efficacy of Agenus's patented "QS-21 Stimulon" adjuvant 

In April 2014, Agenus inked a deal with Merck potentially worth $100 million. Under the terms of that deal, Agenus is using its proprietary Retrocyte Display technology to discover antibodies against a pair of undisclosed checkpoint targets for the treatment of cancer. Agenus has advanced two of its own CPM candidates into early drug development and the company is planning to advance several more antibodies in clinical trials.

Today, Agenus is focused on developing a range of immuno-oncology products, including the Prophage vaccines, multiple checkpoint modulators (also known as checkpoint inhibitors or checkpoint antibodies) and its QS21-Stimulon adjuvant. The company's personalized, heat shock protein-based vaccines are in Phase 2 studies. The QS-21 Stimulon adjuvant platform is partnered with GlaxoSmithKline and Janssen. Several of those collaborations involve Phase 3 trials. Altogether, the company and its partners are sponsoring approximately 20 clinical trials of Agenus products.

Website

http://www.agenusbio.com

Rating GlobalNY.biz

Mentions in the news View all

Subordinate organizations View all

  • Mink Therapeutics

    Mink Therapeutics

    MiNK Therapeutics, Inc. is a biopharmaceutical company. The Company is specialized in discovery, development and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell

    #3049

Quotes

All

Brenda Song Exposes the Cost Behind Disney Childhood Fame

SONG Brenda
SONG Brenda

I just went, ‘Am I having a panic attack?’ And then all of a sudden I remember stars and, gone

Julia Garner Keeps Madonna Biopic Alive Through Uncertainty

GARNER Julia
GARNER Julia

I don’t know. Every hour it changes, in a way

Nicolas Cage Treats Spider-Noir’s Cancellation as Creative Escape

COPPOLA Nicolas
COPPOLA Nicolas

You never wanna get stuck repeating a character and wear out your welcome

Raven-Symoné Confronts the Jealousy Behind Her Sidibe Feud

PERMAN-MADAY Raven
PERMAN-MADAY Raven

What I would say is, like, ‘Don’t bring her around me

Cynthia Erivo Gives Snoop Dogg’s Biopic a Deeper History

BROADUS Calvin
BROADUS Calvin

I get to bring my mother back to life. I get to bring my brother back to life.